{"entity":{"id":"nct06208150","kind":"trial","name":"A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortez","aka":["MonumenTAL-6"],"tldr":"A phase 3 trial of Talquetamab, Pomalidomide, Teclistamab in multiple myeloma, run by Janssen Research & Development, LLC, active and no longer recruiting.","summary":"A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide is a phase 3 interventional study registered as NCT06208150 by Janssen Research & Development, LLC, with 838 participants enrolled, started 2024-01-22 and due to reach its primary completion in 2026-04-01. Interventions recorded: Talquetamab, Pomalidomide, Teclistamab, Elotuzumab, Dexamethasone. Conditions listed: Multiple Myeloma. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06208150","url":"https://clinicaltrials.gov/study/NCT06208150"}],"tags":["ctgov-ingest"],"related":[],"cancers":["multiple-myeloma"],"sections":[],"technologies":["antiemetic-therapy","monoclonal-antibody","protac-degrader","t-cell-engager"],"targets":[],"drugs":["talquetamab","pomalidomide","teclistamab","elotuzumab","dexamethasone","bortezomib"],"companies":["johnson-johnson"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06208150","phase":"3","setting":"64407564MMY3009: A Phase 3 Randomized Study Comparing Talquetamab in Combination With Pomalidomide (Tal-P), Talquetamab in Combination With Teclistamab (Tal-Tec), and Investigator's Choice of Either Elotuzumab, Pomalidomide, and Dexamethasone (EPd) or Pom","sponsor":"Janssen Research & Development, LLC","participation":[{"nct":"NCT06208150","source":"https://clinicaltrials.gov/study/NCT06208150","fetchedAt":"2026-10-07T16:54:19.620Z","studySha256":"19da3a1a45996f9d587a89d2d06f66471a30367c36dd106c93beac8f3f19fc1b","overallStatus":"ACTIVE_NOT_RECRUITING","lastUpdatePosted":"2026-09-25","leadSponsor":"Janssen Research & Development, LLC","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":838,"enrolmentType":"ACTUAL","siteCount":242,"recruitingSiteCount":0,"countries":["Argentina","Australia","Austria","Belgium","Brazil","Canada","China","Czechia","Denmark","France","Germany","Greece","Hungary","India","Israel","Italy","Japan","Mexico","Netherlands","Poland","Saudi Arabia","South Korea","Spain","Sweden","Turkey (Türkiye)","United Kingdom","United States"]}],"started":"2024-01-22","startedType":"actual","enrolled":838,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06208150/","neighbours":{"cancer":[{"id":"multiple-myeloma","kind":"cancer","name":"Multiple myeloma","route":"/cancers/multiple-myeloma/"}],"technology":[{"id":"antiemetic-therapy","kind":"technology","name":"Antiemetics for chemotherapy-induced nausea and vomiting","route":"/technologies/antiemetic-therapy/"},{"id":"monoclonal-antibody","kind":"technology","name":"Monoclonal antibodies","route":"/technologies/monoclonal-antibody/"},{"id":"protac-degrader","kind":"technology","name":"PROTACs & molecular glues (targeted protein degradation)","route":"/technologies/protac-degrader/"},{"id":"t-cell-engager","kind":"technology","name":"T-cell engagers (bispecific)","route":"/technologies/t-cell-engager/"}],"drug":[{"id":"bortezomib","kind":"drug","name":"Bortezomib","route":"/drugs/bortezomib/"},{"id":"dexamethasone","kind":"drug","name":"Dexamethasone","route":"/drugs/dexamethasone/"},{"id":"elotuzumab","kind":"drug","name":"Elotuzumab","route":"/drugs/elotuzumab/"},{"id":"pomalidomide","kind":"drug","name":"Pomalidomide","route":"/drugs/pomalidomide/"},{"id":"talquetamab","kind":"drug","name":"Talquetamab","route":"/drugs/talquetamab/"},{"id":"teclistamab","kind":"drug","name":"Teclistamab","route":"/drugs/teclistamab/"}],"company":[{"id":"johnson-johnson","kind":"company","name":"Johnson & Johnson","route":"/companies/johnson-johnson/"}]}}